TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05273814
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab intravenous infusion 200mg d4
Study: NCT05273814
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed intravenous infusion 500mg/m2 d1
Study: NCT05273814
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemetrexed intravenous infusion 7.5mg/kg，d1
Study: NCT05740631
Drug: Ocaliva
Normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
Study: NCT05157971
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given SC, IV or IT
Study: NCT05157971
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05157971
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM or IV
Study: NCT05157971
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05157971
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05157971
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05556083
Drug: Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet
Normalized name: sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single blind placebo randomized controlled trial
Study: NCT04979793
Drug: L-citrulline
Normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 gram sachet, L-citrulline
Study: NCT05159687
Drug: Atomoxetine Hydrochloride
Normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
Study: NCT06180616
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW.~Modification of study drug will be performed if the participant is experiencing significant side effects and cannot tolerate the higher dosage of the study drug. In this instance, the study drug dosage will be reduced to the previously tolerated dosage and held at this dose for a further 4 weeks. One further attempt at dose escalation will be undertaken after 4 weeks, at the discretion of the participant and the study investigator. If recurrent side effects are experienced by the participant, the study drug will be returned to the previously tolerated dosage, and the prescription continued at this dosage for the remainder of the study.
Study: NCT04535817
Drug: Omalizumab Injection [Xolair]
Normalized name: omalizumab Injection [Xolair]
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg via 2 subcutaneous injections every 4 weeks
Study: NCT04787562
Drug: XNW4107, Imipenem/Cilastatin
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose
Study: NCT00002134
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05369819
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: . Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room
Study: NCT05369819
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room
Study: NCT05627232
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05627232
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05627232
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06106009
Drug: PF-07976016
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, oral suspension or solid oral formulation(s)
Study: NCT06106009
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam oral solution
Study: NCT05143528
Drug: Nilotinib BE 84mg
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 84 mg capsule
Study: NCT05143528
Drug: Nilotinib BE 112 mg
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 112 mg capsule
Study: NCT05755932
Drug: HFO MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA
Study: NCT05025397
Drug: Danavorexton
Normalized name: Danavorexton
DrugBank: Danavorexton (DB16962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danavorexton intravenous infusion.
Study: NCT05025397
Drug: Danavorexton Placebo
DrugBank: Danavorexton (DB16962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danavorexton placebo-matching intravenous infusion.
Study: NCT05025397
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol intravenous bolus.
Study: NCT05025397
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane inhalation.
Study: NCT05025397
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol intravenous infusion.
Study: NCT06310642
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine was available to counteract any potential extrapyramidal side effects of the study drug. The use of Diphenhydramine for this purpose is well established.
Study: NCT06310642
Drug: Prochlorperazine 10 mg
Normalized name: prochlorperazine 10 MG
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the Prochlorperazine arm were administered 10mg PO Prochlorperazine immediately prior to ascent
Study: NCT06409936
Drug: Asciminib
Normalized name: Asciminib
DrugBank: Asciminib (DB12597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: both arms will include asciminib treatment
Study: NCT06409936
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in the arm B the nilotinib will be added on in all patients
Study: NCT04952597
Drug: Ociperlimab
Normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle
Study: NCT04952597
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle
Study: NCT05965583
Drug: BI 1815368
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1815368
Study: NCT05965583
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole
Study: NCT04679623
Drug: Seizalam
Normalized name: Seizalam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Seizalam, 10 mg
Study: NCT06129591
Drug: Lazarus Naturals THC-Free CBD Tincture (flavorless) + Silicone patch
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessment will be done over a period of 6 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale. Statistical analysis will assess whether CBD oil improves short-term and long-term scar appearances.
Study: NCT06129591
Drug: Silicone patch
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-treatment group is included in this study to comply with the standard of care, as to treat post-operative wounds with silicone patches to improve final scar outcomes.
Study: NCT05847660
Drug: Progesterone antagonist
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.
Study: NCT05847660
Drug: conventional antagonist protocol
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
Study: NCT05689671
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg i.v. q3w
Study: NCT05689671
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m² i.v. qw
Study: NCT05689671
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5-6 i.v. q3w
Study: NCT05689671
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg i.v. q3w
Study: NCT05689671
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m² i.v. q3w
Study: NCT05689671
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m² i.v. q3w
Study: NCT06269185
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
Study: NCT06020560
Drug: Dalteparin Prefilled Syringe
Normalized name: dalteparin Prefilled Syringe
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
Study: NCT06020560
Drug: Tinzaparin profiled syringe
Normalized name: tinzaparin sodium Prefilled Syringe
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
Study: NCT06308068
Drug: Diacerein 50 mg Capsule
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein 50 mg Capsule
Study: NCT06269185
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
Study: NCT06304142
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
Study: NCT05033886
Drug: fezolinetant
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05289323
Drug: Neostigmine Methylsulfate
Normalized name: Neostigmine Methylsulfate
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
Study: NCT06233162
Drug: Febuxostat-Test product
Normalized name: febuxostat Oral Product
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India
Study: NCT04985851
Drug: durvalumab + anlotinib
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.
Study: NCT04985851
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: durvalumab
Study: NCT06233162
Drug: Febuxostat-Reference product
Normalized name: febuxostat Oral Product
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 80 mg tablets Manufactured by: Patheon France, France
Study: NCT02603458
Drug: NRX-1074
Normalized name: NRX-1074
DrugBank: NRX-1074 (DB11784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
Study: NCT00000788
Drug: Methadone hydrochloride
Normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000788
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06180499
Drug: T-reg depleted DLI
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treg depleted Donor Lymphocytes Infusion
Study: NCT06479291
Drug: Hydroxychloroquine Oral Tablet
Normalized name: hydroxychloroquine Oral Tablet
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
Study: NCT06479291
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
Study: NCT05684692
Drug: Siltuximab
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A chimeric immunoglobulin G mAb, via intravenous infusion.
Study: NCT05684692
Drug: Erenumab-Aooe
Normalized name: erenumab-aooe
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
Study: NCT05684692
Drug: Siltuximab Matching Placebo
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dextrose 5% in water, via intravenous infusion.
Study: NCT05684692
Drug: Erenumab-Aooe Matching Placebo
Normalized name: erenumab-aooe
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
Study: NCT04754789
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: preloading with high dose statins (atorvastatin 80mg) with loading dose of dual antiplatelet( asprine 300 mg and ticagrelor 180 mg) pre-primary PCI
Study: NCT05535023
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by vein (IV)
Study: NCT03987802
Drug: Faster-acting insulin aspart
Normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT04754789
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading dose of dual antiplatelet (asprine 300 mg and ticagrelor 180 mg)
Study: NCT00002050
Drug: Thymopentin
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05645107
Drug: Xembify
Normalized name: Xembify
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC infusion pump
Study: NCT04017819
Drug: 18F-C-SNAT4
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotracer- Dose 10 mCi
Study: NCT04793204
Drug: fezolinetant
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05111002
Drug: Lefamulin
Normalized name: LEFAMULIN
DrugBank: Lefamulin (DB12825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg tablet orally twice daily
Study: NCT05844735
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT06140251
Drug: Sodium-glucose cotransporter 2 inhibitor
Normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.
Study: NCT06340724
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20 mg tablet twice daily
Study: NCT06340724
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 g tablet three times daily
Study: NCT05223595
Drug: Gentuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gentuximab: 8mg/kg or 12mg/kg intravenous (IV) infusion administered on Day 1 and 15 of each cycle; Almonertinib: 110 mg orally once daily.
Study: NCT04733118
Drug: Trastuzumab and Pertuzumab (FDC SC) and T-DM1
Normalized name: T-DM1
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~* Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~* Cohort B: T-DM1 ± ET for 10 cycles~* Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1.
Study: NCT05139719
Drug: HEC585 dose A
Normalized name: Hec585
DrugBank: Yinfenidone (DB18330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
Study: NCT05139719
Drug: HEC585 dose B
Normalized name: Hec585
DrugBank: Yinfenidone (DB18330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage
Study: NCT06305299
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine 30 mg/m2 IV will be given.
Study: NCT06410352
Drug: Semaglutide, Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day
Study: NCT05607173
Drug: Fexinidazole (HOE239)
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of administration: oral; pharmaceutical form: tablet
Study: NCT04840485
Drug: SHR-1314
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1314 high dose
Study: NCT04840485
Drug: SHR-1314
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1314 low-dose